Catalent today announced the launch of its CosmoPod® Duo softgel capsule technology for the delivery of topical skin treatments.

Catalent today announced the launch of OptiGel® DR technology for the formulation and manufacture of delayed/enteric release softgels. The technology allows softgel capsules to be formed by combining pectin, a naturally derived polysaccharide, with gelatin, eliminating the need for a separate capsule coating step.

Catalent today announced the completion of a $3.2 million expansion program at its consumer health manufacturing facilities in Strathroy, Canada and Sorocaba, Brazil.

Catalent today announced that it will present at the upcoming SupplySide West conference at the Mandalay Bay Resort & Casino, Las Vegas on Oct. 15 – 19, 2019.

Catalent Pharma Solutions today announced that it is to participate in a half-day workshop, along with Euromonitor International, on the formulation of consumer health products, as part of SupplySide West.

Catalent Pharma Solutions today announced it has entered into an exclusive long-term supply agreement to produce the next generation of Pfizer Inc.’s leading over-the-counter (OTC) pain relief product with the launch of new Advil Liqui-Gels Minis.

Catalent Pharma Solutions today announced that it is to launch a new product, Fish Oil Thin Shell EasyBurst® Chewables, at the upcoming Vitafoods Europe Conference.

Catalent Pharma Solutions today announced that it has completed the acquisition of Accucaps Industries Limited (Accucaps).

Catalent Pharma Solutions today announced that it has agreed to acquire Accucaps Industries Limited (Accucaps).